This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SCRN1 / Secernin-1 · IHC design guide
Design Immunohistochemistry for SCRN1
Plan chromogenic IHC for cytoplasmic SCRN1 staining, with cerebral cortex neurons as a positive tissue reference (HPA tissue IHC). The catalog antibody A10002-1 was used at 2 μg/mL in paraffin-section IHC (datasheet A10002-1).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
SCRN1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic, mainly in brain (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining in brain; cortical neurons show medium signal (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A10002-1) | |
| Positive control | Cerebral cortex+1 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific) | |
| Caveat | Staining and RNA show medium consistency; verify specificity (HPA tissue IHC) | |
| Regulation | Brain-enhanced RNA expression (HPA tissue RNA) | |
| Isoform / epitope | 3 isoforms; check whether the epitope spans variants (UniProt) |
Section 1
Recommended SCRN1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet: A10002-1) is accompanied by three published chromogenic SCRN1 protocols (PMC4924679; PMC4357136; PMC9012169).
| Sample | Paraffin-embedded human rectal cancer tissue; fixative not specified (datasheet A10002-1) |
| Fixation | Image fixative and duration unreported (datasheet A10002-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A10002-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A10002-1) |
| Primary antibody | Rabbit anti-SCRN1, 2 μg/ml (datasheet A10002-1) |
| Primary incubation | Overnight at 4 °C (datasheet A10002-1) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A10002-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | SCRN1-positive staining in neuronal cells of cerebral cortex (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic expression mainly in brain. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA, pH 8.0, for the catalog antibody (datasheet: A10002-1). Citrate-based retrieval is a published comparison (PMC4924679; PMC4357136).
Section 2
What Is the Expected SCRN1 Staining Pattern?
SCRN1 is expected in the cytoplasm, consistent with its lack of a transmembrane segment (UniProt Q12765: cytoplasm; topology). In paraffin sections, look for neuronal staining in cerebral cortex and staining of non-germinal center cells in tonsil, both reported at Medium intensity (HPA tissue IHC). HPA rates the tissue profile Enhanced, while noting medium consistency with RNA data and pending external verification (HPA tissue IHC).
| Cerebral cortex shows cytoplasmic staining in neuronal cells at about Medium intensity. | This matches the reported cell type, compartment and level (HPA tissue IHC: cerebral cortex, neuronal cells, Medium; UniProt Q12765: cytoplasm). Judge the pattern in identifiable cells rather than the overall darkness of the section (general IHC practice). |
| Staining is predominantly nuclear or sharply outlines cell membranes. | That compartment conflicts with the reported cytoplasmic and cytosolic localization (UniProt Q12765: cytoplasm and no transmembrane segment; HPA subcellular: cytosol). Treat it as questionable until controls and a repeated run support its specificity (general IHC practice). |
| Adipocytes in adipose tissue stain prominently, or adrenal glandular cells appear positive. | Both cell populations are reported as Not detected (HPA tissue IHC). Investigate cross-reactivity or endogenous chromogenic activity before calling the signal SCRN1 (general IHC practice). A single discordant section does not identify which cause applies. |
| Color spreads across tissue and empty areas without a clear cellular pattern. | Diffuse deposit does not support the reported cytoplasmic pattern (HPA tissue IHC: cytoplasmic expression). Background can arise from nonspecific antibody binding or detection chemistry; compare staining controls and tissue-free areas (general IHC practice). |
| No neuronal signal is visible in an otherwise intact cerebral cortex section. | This misses a reported Medium positive population (HPA tissue IHC: cerebral cortex, neuronal cells). First assess the run and the identity of the sampled cells; absence alone cannot distinguish technical failure from variation in the specimen (general IHC practice). |
💡Expected SCRN1 appearanceCall a positive result when identifiable cerebral cortical neurons show mainly cytoplasmic, approximately Medium chromogenic staining (HPA tissue IHC; UniProt Q12765: cytoplasm); dominant nuclear, membrane-only or cell-free color is a questionable positive (general IHC practice).
| Cell and tissue context | HPA reports Medium staining in cortical neurons and tonsillar non-germinal center cells, Low staining in several other listed populations, and Not detected staining in listed negative populations (HPA tissue IHC). Interpret intensity against the specific cell type, not the tissue name alone (general IHC practice). |
| Subcellular location | SCRN1 is annotated as cytoplasmic, with no transmembrane segment (UniProt Q12765), and HPA places it in the cytosol by ICC-IF (HPA subcellular). These observations support a cytoplasmic IHC call; they do not establish a target-specific antigen retrieval condition. |
| Antibody and profile validation | The supplied antibody HPA024517 has Enhanced IHC validation (HPA antibodies). The tissue profile is also rated Enhanced, but HPA describes medium consistency with RNA and pending external verification (HPA tissue IHC). Keep discordant staining provisional. |
| Isoform coverage | UniProt lists 3 SCRN1 isoforms (UniProt Q12765: isoforms 1, 2 and 3). The supplied evidence does not map the IHC antibody epitope or establish which isoforms it detects, so do not assign an unexpected pattern to a particular isoform. |
| ICC-IF comparison | HPA reports an approved cytosolic ICC-IF location and lists A-431, U-251MG and U2OS among imaged cell lines (HPA subcellular; HPA antibodies: ICC Approved). This supports a compartment comparison; ICC-IF images do not set an IHC staining intensity or supply an IF protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| Cortical neurons have no detectable chromogenic signal. | A reported Medium population is missing (HPA tissue IHC); the cause is unresolved from the slide alone. | Confirm neuronal morphology and that the control section developed; review antibody dilution, antigen retrieval and detection records, then repeat with a positive control (general IHC practice). No SCRN1-specific retrieval setting is supplied. |
| Staining is mainly nuclear or restricted to cell outlines. | The compartment conflicts with cytoplasmic SCRN1 and HPA's cytosolic ICC-IF location (UniProt Q12765; HPA subcellular). | Compare with a staining control and review morphology and chromogen deposits; repeat the IHC run if the compartment remains unclear (general IHC practice). Do not score the discordant compartment as confirmed SCRN1. |
| Adipose adipocytes or adrenal glandular cells stain strongly. | Those populations are listed as Not detected (HPA tissue IHC); cross-reactivity or endogenous detection activity is possible (general IHC practice). | Compare a no-primary control and inspect whether color follows cells or endogenous pigment; reassess the call against an HPA-listed positive population (general IHC practice). |
| A uniform haze obscures neuronal cytoplasm. | Nonspecific binding or excess chromogenic deposit can obscure cellular localization (general IHC practice). | Check a no-primary control, washing and development time; adjust blocking or antibody dilution within the laboratory's validated workflow (general IHC practice). Reassess only when cell boundaries are readable. |
| Tonsil and cortex appear to have different staining strengths. | HPA reports Medium staining for specified cells in both tissues, but the supplied evidence does not define a quantitative equality between sections (HPA tissue IHC). | Compare the named cell populations under matched processing and detection conditions; record compartment and cell type before comparing intensity (general IHC practice). |
| Does an ICC-IF cytosolic image validate an IHC-P result? | HPA approves the cytosolic ICC-IF location, while the IHC tissue profile has its own reliability caveat (HPA subcellular; HPA tissue IHC). | Use ICC-IF as compartment context only; judge paraffin-section staining against IHC cell patterns and controls (general IHC practice). Consult the separate IF/ICC guide for that application. |
Experiment evidence
IHC & IF images showing SCRN1 staining
A10002-1 · IHCIHC analysis of SCRN1 using anti-SCRN1 antibody (A10002-1). SCRN1 was detected in a paraffin-embedded section of human rectal cancer tissue.
A10002-1 · IHCIHC analysis of SCRN1 using anti-SCRN1 antibody (A10002-1). SCRN1 was detected in a paraffin-embedded section of human gall bladder adenosqu
A10002-1 · IFIF analysis of SCRN1 using anti-SCRN1 antibody (A10002-1). SCRN1 was detected in an immunocytochemical section of U20S cells. Enzyme antigen
A10002 · IHCImmunohistochemistry of SCRN1 in human kidney tissue with SCRN1 antibody at 5 μg/mL.
A10002 · IFImmunofluorescence of SCRN1 in Human Kidney cells with SCRN1 antibody at 20 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000136193-SCRN1/tissue/cerebral+cortex#imid_6435072
HPA · CerebellumHuman Protein Atlas IHC, Cerebellum. Source: https://www.proteinatlas.org/ENSG00000136193-SCRN1/tissue/cerebellum#imid_6435083
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000136193-SCRN1/tissue/colon#imid_6453311
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000136193-SCRN1/tissue/liver#imid_6453310
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA024517; green = SCRN1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA024517; green = SCRN1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for SCRN1 IHC & IF
🧪Run cerebral cortex first and expect staining in neuronal cells (HPA: Medium in cerebral cortex neuronal cells). Use adipose tissue as the negative tissue, focusing on adipocytes (HPA: Not detected in adipocytes); compare neighboring non-neuronal cells on the cortex slide as an internal background reference without assuming they are SCRN1-negative.
Positive control tissue: Cerebral cortex (Neuronal cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show SCRN1 in A-431, U-251MG, U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control, an isotype control matched to the primary antibody’s host species and clonality, and a SCRN1 knockout sample or validated antigen-peptide block. Quench endogenous peroxidase and check for endogenous biotin when using the caption’s biotin-based DAB detection (selected-SKU tissue-IHC caption: biotinylated secondary, SABC and DAB).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the fixative in the selected-SKU paraffin-section caption is unreported (selected-SKU tissue-IHC caption). Start retrieval optimization from heat-mediated EDTA at pH 8.0, which was used in that caption; the supplied evidence does not establish whether frozen sections or IF are easier for SCRN1. In cerebral cortex, distinguish DAB staining from intrinsic pigment during scoring and assess autofluorescence separately if using IF (standard IHC/IF practice).
HPA tissue IHC evidence for SCRN1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebral cortex | Neuronal cells | Medium | Protein (IHC) | HPA → |
| Tonsil | Non-germinal center cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced SCRN1 IHC Tips
Troubleshoot SCRN1 staining in paraffin sections by checking retrieval, specimen handling, cytoplasmic localisation, detection background, and cell-specific scoring.
Which retrieval condition should I try first for weak SCRN1 staining?
Start with heat-mediated retrieval in EDTA at pH 8.0 for SCRN1 paraffin-section IHC (datasheet A10002-1). Keep section thickness, heating method, cooling interval, and detection chemistry constant while comparing runs, because each can change staining intensity (standard IHC practice). The documented workflow used 2 μg/ml primary antibody overnight at 4°C, followed by a biotinylated secondary and DAB development (datasheet A10002-1). If staining remains weak, compare another retrieval buffer or heating duration with the original EDTA condition on adjacent sections (standard IHC practice). Judge improvement by cytoplasmic contrast in expected cells, consistent with SCRN1 localisation (UniProt Q12765; HPA: cytosol).
How should I handle weak SCRN1 staining when fixation history is uncertain?
Target-specific fixation sensitivity is unknown, and the documented paraffin-section image does not report its fixative (datasheet A10002-1). Record the fixative, fixation duration, tissue thickness, and processing history before comparing specimens; variation in these factors can affect IHC staining (standard IHC practice). Run sections from specimens with known processing histories together, using the same EDTA pH 8.0 retrieval and detection conditions (datasheet A10002-1; standard IHC practice). Check whether weak signal tracks with processing history or occurs across the entire run, including reference sections (standard IHC practice). Do not assign a SCRN1-specific fixation effect without a controlled comparison (standard IHC practice).
Where should SCRN1 staining appear, and what pattern warrants investigation?
Expect predominantly cytoplasmic staining: SCRN1 is annotated as cytoplasmic, with no transmembrane segment (UniProt Q12765), and its approved subcellular location is cytosol (HPA: subcellular). For tissue controls, neuronal cells in cerebral cortex and non-germinal center cells in tonsil show medium staining (HPA: tissue IHC). Compare staining with cell morphology and the counterstain before calling sharply nuclear or membrane-restricted signal positive (standard IHC practice; UniProt Q12765). Examine adjacent sections for staining confined to folds, edges, or damaged regions, which can mimic a compartmental pattern (standard IHC practice). Document mixed patterns separately instead of folding them into a cytoplasmic score (standard IHC practice).
Could isoforms or processing explain inconsistent SCRN1 staining?
SCRN1 has 3 annotated isoforms, but the supplied product evidence does not specify which epitopes the antibody recognizes (UniProt Q12765; datasheet A10002-1). Its annotated mature chain spans residues 2–414, with N-acetylalanine at residue 2 and no annotated glycosylation sites or domains (UniProt Q12765). Those annotations alone cannot establish whether processing or alternative splicing changes antibody binding in paraffin sections (UniProt Q12765; standard IHC practice). Check epitope documentation, if available, against isoform sequences before interpreting selective loss of staining (standard IHC practice). Compare adjacent sections and independent controls under identical retrieval conditions to separate epitope concerns from processing variation (standard IHC practice).
How can IF help assess a questionable SCRN1 IHC pattern?
Use IF as an orthogonal localisation check while keeping the paraffin-section IHC result as the primary readout (standard IHC practice). Pair SCRN1 with a neuronal marker when assessing cerebral cortex, where neuronal cells show medium SCRN1 staining (HPA: tissue IHC). Choose a fluorophore channel with low specimen autofluorescence, and include single-label controls to evaluate bleed-through in multiplex images (standard IF practice). Because SCRN1 is cytosolic and has no transmembrane segment, use permeabilisation suited to an intracellular epitope and verify that cell morphology remains intact (HPA: subcellular; UniProt Q12765; standard IF practice). Assess agreement in cells and compartment, without assuming that the IHC antibody has IF validation (standard IF practice).
What should I check when SCRN1 DAB staining is diffuse or patchy?
The documented workflow used 10% goat serum blocking, a biotinylated secondary, an avidin-biotin detection complex, and DAB (datasheet A10002-1). Run a no-primary control and inspect whether staining persists, especially in damaged tissue or regions with endogenous pigment (standard IHC practice). Check peroxidase blocking, endogenous biotin interference, secondary-antibody background, and DAB development time as separate possible sources of signal (standard IHC practice). Compare suspect regions with an intact reference section processed in the same run and with the same EDTA pH 8.0 retrieval (datasheet A10002-1; standard IHC practice). Score only staining distinguishable from the control background (standard IHC practice).
How should I quantify SCRN1 across heterogeneous tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and anatomical region before scoring, then record cytoplasmic staining separately from any unexpected compartmental signal (UniProt Q12765; standard IHC practice). For a defined cell population, report the percentage of positive intact cells and an H-score combining that percentage with intensity; use cell density per mm² when counting discrete positive cells (standard IHC practice). Normalise counts to the evaluated tissue area or eligible cell population, and exclude folds, necrosis, and poorly preserved regions (standard IHC practice). Keep retrieval, exposure to DAB, counterstaining, and scoring thresholds consistent across sections (standard IHC practice). Record cell types separately because tissue expression varies (HPA: tissue IHC).
How do I distinguish convincing SCRN1 positivity from staining artefact?
Look for reproducible cytoplasmic staining in morphologically intact cells, consistent with SCRN1 localisation (UniProt Q12765; HPA: subcellular). Cerebral-cortex neuronal cells and tonsil non-germinal center cells offer reported medium-staining comparators, whereas adipose-tissue adipocytes were not detected (HPA: tissue IHC). Investigate isolated nuclear or membrane-only staining, edge effects, necrotic patches, and signal retained in no-primary controls before calling a section positive (standard IHC practice; UniProt Q12765). Endogenous enzyme activity or detection-system background can create chromogenic signal, so compare suspect areas with appropriately processed controls (standard IHC practice). Treat discordant staining cautiously because HPA reports medium staining–RNA consistency and pending external verification (HPA: tissue IHC).
Boster reagents
Best SCRN1 / Secernin-1 IHC Antibodies
The catalog shows SCRN1 IHC images in human rectal cancer and kidney tissue, plus IF images in U20S and human kidney cells (catalog image captions).
Real IHC data
Anti-SCRN1 Antibody ®
Cat # A10002-1
Real IHC data
Anti-Secernin-1 SCRN1 Antibody
Cat # A10002
A10002-1 has IHC images from human paraffin sections and an IF/ICC image from U20S cells (A10002-1 image captions). A10002 has an IHC image from human kidney tissue and an IF image from human kidney cells (A10002 image captions).
Which to pick: For paraffin-section IHC, choose A10002-1 when you want a documented starting condition: 2 μg/mL after heat retrieval in EDTA, pH 8.0; its caption does not report the fixative (A10002-1 IHC caption). For IF/ICC, A10002-1 lists both applications and shows U20S cells at 5 μg/mL, while A10002 lists IF and shows human kidney cells at 20 μg/mL (catalog applications; respective IF captions). Both list human, mouse and rat reactivity, but the supplied IHC/IF images show human samples only; neither catalog entry reports a clone (catalog reactivity and image captions; catalog clone fields).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q12765 (SCRN1_HUMAN, Secernin-1).
- Human Protein Atlas. SCRN1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. SCRN1 subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. SCRN1 antibody validation summary (1 antibodies).
- Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation. Oncotarget 2016 — PMC4924679.
- Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies. Acta neuropathologica communications 2019 — PMC6892024.
- Secernin-1 contributes to colon cancer progression through enhancing matrix metalloproteinase-2/9 exocytosis. Disease markers 2015 — PMC4357136.
- The Sertoli cell expressed gene secernin-1 (Scrn1) is dispensable for male fertility in the mouse. Developmental dynamics : an official publication of the American Association of Anatomists 2021 — PMC9012169.
- PubMed PMID:16630140 — UniProt-cited evidence.
- PubMed PMID:8724849 — UniProt-cited evidence.
- PubMed PMID:12168954 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for SCRN1 (Secernin-1). Expected localisation Cytoplasmic, mainly in brain (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A10002-1). Validated IHC antibody: A10002-1 at 2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cerebral cortex (Neuronal cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human rectal cancer tissue; fixative not specified (datasheet A10002-1); 2. Fixation: Image fixative and duration unreported (datasheet A10002-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A10002-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A10002-1); 8. Primary antibody: Rabbit anti-SCRN1, 2 μg/ml (datasheet A10002-1); 9. Primary incubation: Overnight at 4 °C (datasheet A10002-1). Watch for: Fixation: Keep fixation consistent across paraffin sections. (standard IHC practice; not target-specific); Caveat: Staining and RNA show medium consistency; verify specificity (HPA tissue IHC); Isoform / epitope: 3 isoforms; check whether the epitope spans variants (UniProt); Regulation: Brain-enhanced RNA expression (HPA tissue RNA). Evidence: UniProt Q12765, HPA tissue IHC · Enhanced, HPA ICC-IF · cytosol., Datasheet A10002-1, PMC4924679, PMC4357136. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/SCRN1/immunohistochemistry-ihc-guide.